Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

CompletedOBSERVATIONAL
Enrollment

230

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

September 18, 2024

Study Completion Date

January 20, 2025

Conditions
Esophageal CancerOesophageal CancerSiewert Type I Adenocarcinoma of Esophagogastric JunctionSiewert Type III Adenocarcinoma of Esophagogastric Junction
Interventions
PROCEDURE

Elective Surgery for gastric cancer

Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach

Trial Locations (18)

Unknown

N.Alexandrov National Cancer Centre of Belarus, Minsk

Bryansk Regional Oncological Hospital, Bryansk

Cheboksary Republican Clinical Oncology Dispensary, Cheboksary

M.Sigal Republican Medical Oncology Dispensary, Kazan'

A.Loginov Moscow Clinical Scientific Center, Moscow

Moscow City Oncology Hospital № 62, Moscow

P.Herzen Moscow Oncological Research Institute, Moscow

S.Yudin Moscow Oncological Center No.1, Moscow

University Clinical Hospital №1 of Sechenov University, Moscow

University Clinical Hospital №4 of Sechenov University, Moscow

Vishnevsky National Medical Research Center of Surgery, Moscow

Nizhny Novgorod Regional Clinical Oncological Dispensary, Nizhny Novgorod

Novosibirsk Regional Clinical Oncology Dispensary, Novosibirsk

A.Tsyb Medical Radiological Research Centre, Obninsk

Rostov-on-Don National Medical Research Centre for Oncology, Rostov-on-Don

Leningrad Regional Clinical Hospital, Saint Petersburg

Saratov Regional Clinical Oncological Dispensary, Saratov

Ufa Republican Clinical Oncology Dispensary, Ufa

All Listed Sponsors
collaborator

National Medical Research Radiological Centre of the Ministry of Health of Russia

OTHER

lead

P. Herzen Moscow Oncology Research Institute

OTHER_GOV

NCT06277921 - Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery | Biotech Hunter | Biotech Hunter